Featured ArticlesLatest NewsSkincareThe Latest

A Double-Blind Randomized Pilot Study Evaluating the Safety and Efficacy of Topical MEP in the Facial Appearance Improvement of Estrogen Deficient Females

By June 3, 2025No Comments
Journal of Drugs in Dermatology JDD Article About A Double-Blind Randomized Pilot Study Evaluating the Safety and Efficacy of Topical MEP in the Facial Appearance Improvement of Estrogen Deficient Females

JDD From the Vault: Estrogen Deficient Skin: A Topical Option for Postmenopausal Facial Aging

Have you seen this one? We’re highlighting a frequently visited JDD article from the vault that continues to draw attention.

Postmenopausal women often experience dryness, laxity, atrophy, and dullness due to estrogen-deficient skin (EDS), and many are seeking non-hormonal ways to address these changes. This 2018 JDD study evaluated a novel approach: topical methyl estradiolpropanoate (MEP), a “soft estrogen” that offers estrogen-like effects in the skin but is metabolized to an inactive compound, minimizing systemic risk.

In the 14-week study, MEP significantly improved clinical signs of aging compared to vehicle, with no hormonal side effects. It may offer dermatologists a safe, effective cosmeceutical option for patients concerned about postmenopausal facial aging.

J Drugs Dermatol. 2022;21(9); 1012-1013. doi:10.36849/JDD.6795